SCHEMBL3915511

SCHEMBL3915511

CC(C)(Cc1ccc(N2CC(=O)NS2(=O)=O)c(OCc2ccccc2)c1)C(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 6/20 0.42
MAPT P10636 3/20 0.36
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
MRGPRX1 Q96LB2 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PKM P14618 1/20 0.34
ATM Q13315 1/20 0.34
PTPN2 P17706 1/20 0.34
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium SCHEMBL3917394 0.99 PTPN1 (0.41) PTPN1MAPTPOLBTHRBALDH1A1
SCHEMBL3917392 0.99 PTPN1 (0.41) PTPN1MAPTPOLBTHRBALDH1A1
SCHEMBL2933416 0.85 PTPN1 (0.48) PTPN1MAPTPOLBALDH1A1SMN1; SMN2
SCHEMBL647267 0.82 MRGPRX4 (0.43) PTPN1MAPTSMN1; SMN2RXRARXRB
SCHEMBL3917756 0.82 PTPN1 (0.42) PTPN1MAPTALDH1A1MEN1KMT2A
SCHEMBL649136 0.82 PTPN1 (0.44) PTPN1MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL3917093 0.82 PTPN1 (0.42) PTPN1MAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL646919 0.81 PTPN1 (0.47) PTPN1MAPTALDH1A1NPC1RAB9A
SCHEMBL648083 0.81 MEN1 (0.46) PTPN1MAPTALDH1A1SMN1; SMN2NPC1
Potassium SCHEMBL3929625 0.81 PTPN1 (0.41) PTPN1MAPTALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC PTPN1 21/4885MAPT 3315/4885POLB 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.